logo
Share SHARE
FONT-SIZE Plus   Neg

Santarus NDA For Inflammatory Bowel Disease Therapy Uceris Accepted By FDA

Santarus Inc. (SNTS) Wednesday reported that the United States Food and Drug Administration, or FDA, accepted for filing its New Drug Application, or NDA, seeking approval to market Uceris tablets as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review by mid-October 2012.

The NDA seeks to market Uceris in a 9 milligram, or mg, tablet. Also, Cosmo Pharmaceuticals SpA-owned Cosmo Technologies Ltd., a collaborator in the development of Uceris, is now eligible to $4 million in cash or stock as a milestone payment, Santarus Said.

A form of inflammatory bowel disease, or IBD, ulcerative colitis can cause inflammations and ulcers along the colon, resulting in such effects as diarrhea, frequent bowel movements and bleeding. About 1.4 million Americans suffer from IBDs. Uceris is the trade name for budesonide, which is a corticosteroid with topical anti-inflammatory properties.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
New York's landmark Waldorf Astoria hotel will be shut for up to three years starting spring 2017 as its Chinese owner Anbang Insurance Group Co. plans to convert most of its 1,413 hotel rooms into luxury condominiums, according to media reports. Starbucks Corp., for the first time, will offer a single-origin coffee from India to customers in the U.S. under an expansion of the specialty coffee retailer's joint venture partnership with Indian conglomerate Tata Group. Starbucks customers in the U.S. will be able to experience a rare, small-lot coffee from the Tata Nullore Estates located in the Coorg region of India. For the Independence Day week-end, starting June 30, travel volume will be a record this year, predicts the American Automobile Association or AAA. Friday and Monday afternoons are expected to be the peak hours. Cruising seems to be a favorite travel mode this year with 35 percent increase from last...
comments powered by Disqus
Follow RTT